ADMA Biologics (ADMA) Rebound Puts Its Yield Expansion Narrative And Fair Value In Focus
ADMA Biologics (ADMA) has drawn investor attention after recent trading swings, with the share price at $9.81 and a year to date return that is down 45% despite a strong 3 year record.
Recent trading has swung sharply for ADMA Biologics, with a 1 day share price return of 3.21% and a 7 day share price gain of 13.94% sitting against a year to date share price decline of 45.13%. Over a longer period, the 3 year total shareholder return stands at 176.34%, and the 5 year total shareholder return is a little over 7x the starting point. This indicates that, despite the recent declines, the longer term picture has been very strong.
Scan how ADMA Biologics compares with other potential rebound candidates by reviewing our curated list of 29 high quality undervalued stocks.
After a sharp rebound in ADMA Biologics following a steep year to date decline, investors face a straightforward decision: step in after this bounce or wait for a clearer margin of safety as the valuation case unfolds next.
Most Popular Narrative: 44% Undervalued
Against the latest $9.81 close, the most followed ADMA Biologics narrative points to a fair value of $17.60, which frames the recent rebound as only a partial catch up to that implied worth.
Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.
See why 47 investors see ADMA Biologics as 44% undervalued.
Result: Fair Value of $17.60 (UNDERVALUED)
Still, the ADMA Biologics story hinges on successful execution of its yield enhancement process, and on plasma collection and IVIG market conditions not turning more challenging.
Find out about the key risks to this ADMA Biologics narrative.
Next Steps
Skeptical about whether the market is getting ADMA Biologics wrong or right today, and want your view to be based on more than headlines and sentiment? Move quickly through the key positives the market is watching by reviewing the 3 key rewards.
Looking for more ADMA Biologics sized ideas?
If you only focus on ADMA Biologics, you could miss other opportunities that fit your style, risk tolerance, and return goals just as well.
- Target higher income potential by scanning companies in the 7 dividend fortresses that prioritize consistent cash returns to shareholders.
- Spot sturdier businesses early by using the list of solid balance sheet and fundamentals (23 results) to find firms with stronger finances and cleaner balance sheets.
- Hunt for future leaders before the crowd notices them by reviewing the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com